Survival, treatment patterns, and costs of HER2+ metastatic breast cancer patients in Ontario between 2005 to 2020.
Soo Jin SeungH SaherawalaD MoldaverS ShokarC AmmendoleaC Brezden-MasleyPublished in: Breast cancer research and treatment (2023)
The baseline characteristics and treatment patterns for patients who received HER2-TT in our study align with previously reported results. However, the mOS observed for 2L T-DM1 was shorter than that found in pivotal, clinical trial literature. As expected, anti-cancer systemic therapy costs were the main contributor to the over quarter-million dollar mean cost per patient on pert_tras in 1L.
Keyphrases
- clinical trial
- metastatic breast cancer
- end stage renal disease
- systematic review
- ejection fraction
- newly diagnosed
- type diabetes
- case report
- prognostic factors
- combination therapy
- stem cells
- metabolic syndrome
- mesenchymal stem cells
- bone marrow
- peritoneal dialysis
- replacement therapy
- weight loss
- highly efficient
- phase ii
- cell therapy